Curis Lifesciences IPO
GMP, Subscription, Price, Dates & Financial Details
Curis Lifesciences LimitedIncorporation Year: 2010 Headquarters: Sanand, Gujarat, IndiaOverview: Curis Lifesciences Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of high-quality pharmaceutical products. The company operates globally…
Open Date
Fri, 07 Nov 2025
Close Date
Tue, 11 Nov 2025
Price Band
₹ 120 – 128
Lot Size
1000
Issue Size
₹ 27.52 Cr
Minimum Investment
₹ 256,000 (2000 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Curis Lifesciences IPO has successfully completed its IPO process and is now listed on NSE SME Platform. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹27.52 Crore.
The Curis Lifesciences IPO remained open for subscription from November 07, 2025, to November 11, 2025. The basis of allotment was finalized on November 12, 2025, and the company's shares were listed on NSE SME Platform on November 14, 2025.
The company had fixed the price band at ₹120 to ₹128 per share, with a lot size of 1000 shares. Retail investors were required to make a minimum investment of ₹256,000 (based on the upper price band) to apply for one lot.
MUFG Intime India Private Limited served as the registrar to the issue. Swastika Investmart Ltd acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Curis Lifesciences Limited is now a publicly listed company on NSE SME Platform. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Curis Lifesciences IPO Timeline (Tentative)
- IPO Open Date
- Fri, 07 Nov 25
- IPO Close Date
- Tue, 11 Nov 25
- Basis of Allotment
- Wed, 12 Nov 25
- Initiation of Refunds
- Thu, 13 Nov 25
- Credit of Shares to Demat
- Thu, 13 Nov 25
- Listing Date
- Fri, 14 Nov 25 — NSE & BSE
Open Date
07 November 2025
Close Date
11 November 2025
Basis Of Allotment
12 November 2025
Listing Date
14 November 2025
IPO Subscription
Check Live Subscription →The Curis Lifesciences IPO has received bids for 10,67,12,000 shares against 14,33,000 shares offered, resulting in an overall subscription of 74.47x. the NII category is subscribed 115.81x, Retail Investors 44.28x, and QIBs 96.17x. Within the NII category, BNII is subscribed 143.26x, while SNII is subscribed 60.38x.
QIB
96.17x
NII
115.81x
BNII
143.26x
SNII
60.38x
RII
44.28x
Total
74.47x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 7,16,000 shares, representing 49.97% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 4,09,000 shares (28.54%), while Non-Institutional Investors (NIIs) receive 3,08,000 shares (21.49%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 409,000 | 28.54% |
| Non-Institutional | 308,000 | 21.49% |
| BNII | 206,000 | 14.38% |
| SNII | 102,000 | 7.12% |
| Retail Investors | 716,000 | 49.97% |
| Total | 1,433,000 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 50.12 | 33.82 | 29.67 | 27.4 |
| Revenue | 36.91 | 35.89 | 36.39 | 23.76 |
| Profit After Tax | 5.3 | 5.03 | 1.85 | 0.49 |
| Net Worth | 15.53 | 5.97 | 0.95 | 0.9 |
| Reserve & Surplus | 9.59 | 5.47 | 0.45 | -1.4 |
| Total Borrowings | 16.16 | 17.09 | 16.19 | 17.62 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Curis Lifesciences Limited KPI Information
| Particular | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| ROE % | 145.2 | 8322.25 | -42.52 |
| ROCE % | 34.89 | 20.38 | 17 |
| Debt / Equity | 2.86 | 17.08 | -19.5 |
| RoNW % | 84.12 | 195.28 | -54.5 |
| Pat Margin % | 14.13 | 5.23 | 2.07 |
Peers Comparison
No Peer Comparision Available
About Curis Lifesciences Limited
Curis Lifesciences Limited
Incorporation Year: 2010
Headquarters: Sanand, Gujarat, India
Overview:
Curis Lifesciences Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of high-quality pharmaceutical products. The company operates globally and domestically, offering services on a loan license, contract manufacturing, and own brand marketing basis.
Operations:
Curis Lifesciences manufactures pharmaceutical formulations for over 100 corporate clients under loan license and contract manufacturing arrangements. In addition, the company markets its own brands in Yemen and Kenya, serving two international clients under its brand portfolio.
Product Portfolio:
- General pharmaceutical tablets and capsules
- Oral liquids
- External preparations (topical formulations)
- Sterile ophthalmic ointments
Manufacturing Facility:
The company operates a state-of-the-art manufacturing facility located in Sanand, Gujarat, equipped with advanced technology and robust quality assurance systems. The facility complies with stringent regulatory and quality control standards to ensure the safety, efficacy, and reliability of all products.
Workforce:
As of July 31, 2025, Curis Lifesciences Limited employs 95 permanent staff members, comprising skilled professionals across manufacturing, quality assurance, research, and administrative functions.
Curis Lifesciences IPO Promoters
- Mr. Dharmesh Dashrathbhai Patel
- Mr. Siddhant Jayantibhai Pawasia
- Mr. Piyush Gordhanbhai Antala
- Mr. Jaimik Mansukhbhai Patel
Promoters Holding
Holding Pre Issue
92.68%
Holding Post Issue
68.03%
Curis Lifesciences IPO Objective
The Company Curis Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities
- Capital Expenditure towards Construction of a Storage Facility
- Pre-payment/Repayment of outstanding Secured Loans
- Product Registrations in other countries
- Funding our Working Capital Requirements
- General Corporate Purposes
Curis Lifesciences Limited Address / Contact Details
Curis Lifesciences Ltd.
PF-23, GIDC Sanand - II,
Industrial Estate,Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
IPO Snapshot
Curis Lifesciences IPO Lot Size
The Curis Lifesciences IPO has a lot size of 1,000 shares. Retail investors require a minimum investment of ₹2,56,000 by applying for 2 lot (2,000 shares). The maximum application allowed for the retail category is 2 lots (2,000 shares), requiring an investment of ₹2,56,000.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | 256,000.00 |
| Retail (Max) | 2 | 2,000 | 256,000.00 |
| S-HNI (Min) | 3 | 3,000 | 384,000.00 |
| S-HNI (Max) | 7 | 7,000 | 896,000.00 |
| B-HNI (Min) | 8 | 8,000 | 1,024,000.00 |
Issue Reservation
- QIB — 28.54%
- NII — 21.49%
- RII — 49.97%
Book Running Lead Managers
- Swastika Investmart Ltd
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Curis Lifesciences IPO?
Curis Lifesciences IPO is a Book-building IPO with a total issue size of ₹27.52 crore. The Curis Lifesciences IPO price band is ₹120 to 128 per share. The Curis Lifesciences IPO subscription opens on Fri, Nov 7, 2025, and closes on Tue, Nov 11, 2025. The Curis Lifesciences IPO will be listed on the NSE. MUFG Intime India Private Limited is the registrar for the Curis Lifesciences IPO.
When will the Curis Lifesciences IPO open for subscription?
The Curis Lifesciences IPO opens on Fri, Nov 7, 2025 and closes on Tue, Nov 11, 2025
What is Curis Lifesciences IPO Price Band?
Curis Lifesciences IPO Price Band is ₹120 to 128 per share.
What is Curis Lifesciences IPO Lot Size?
Curis Lifesciences IPO lot size is 1000 shares, Retail investors need a minimum investment of ₹256000 based on the upper price band
What is the minimum investment for Curis Lifesciences IPO?
The minimum investment for Curis Lifesciences IPO is ₹256000, based on one lot of 1000 shares at the upper price band of ₹128 per share.
How to apply for Curis Lifesciences IPO?
Investors can apply for the Curis Lifesciences IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Tue, Nov 11, 2025. The application amount remains blocked until the Curis Lifesciences IPO allotment is finalized.
What is Curis Lifesciences IPO Issue Size?
Curis Lifesciences IPO issue size is ₹27.52 crores.
What is the Curis Lifesciences IPO Allotment Date?
Curis Lifesciences IPO allotment date is Wed, Nov 12, 2025.
Who is the Curis Lifesciences IPO Registrar?
The registrar for Curis Lifesciences IPO is MUFG Intime India Private Limited. Investors can go to MUFG Intime India Private Limited website to check Curis Lifesciences IPO allotment status, refund processing, and other IPO-related information.
What is the Curis Lifesciences IPO GMP?
The Curis Lifesciences IPO GMP (Grey Market Premium) is ₹9 as of Fri, Nov 14, 2025. Based on the upper price band of ₹128 per share, the estimated Curis Lifesciences IPO listing price is ₹137, indicating a potential listing gain of approximately 7.03% over the issue price.
Who is the Curis Lifesciences IPO Lead Manager?
The book-running lead managers (BRLMs) for the Curis Lifesciences IPO are Swastika Investmart Ltd. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Curis Lifesciences IPO Red Herring Prospectus (RHP).